Gu Wen-Quan, Cai Sun-Mei, Liu Wei-Dong, Zhang Qi, Shi Ying, Du Li-Juan
Department of Radiology, Punan Hospital, Shanghai 200126, China.
World J Clin Cases. 2022 Jan 14;10(2):485-491. doi: 10.12998/wjcc.v10.i2.485.
Early-stage breast cancer patients often lack specific clinical manifestations, making diagnosis difficult. Molybdenum target X-ray and magnetic resonance imaging (MRI) examinations both have their own advantages. Thus, a combined examination methodology may improve early breast cancer diagnoses.
To explore the combined diagnostic efficacy of molybdenum target X-ray and MRI examinations in breast cancer.
Patients diagnosed with breast cancer at our hospital from March 2019 to April 2021 were recruited, as were the same number of patients during the same period with benign breast tumors. Both groups underwent molybdenum target X-ray and MRI examinations, and diagnoses were given based on each exam. The single ( X-ray or MRI) and combined ( using both methods) diagnoses were counted, and the MRI-related examination parameters ( T-wave peak, peak and early enhancement rates, and apparent diffusion coefficient) were compared between the groups.
In total, 63 breast cancer patients and 63 benign breast tumor patients were recruited. MRI detected 53 breast cancer cases and 61 benign breast tumor cases. Molybdenum target X-ray detected 50 breast cancer cases and 60 benign breast tumor cases. The combined methodology detected 61 breast cancer cases and 61 benign breast tumor cases. The sensitivity (96.83%) and accuracy (96.83%) of the combined methodology were higher than single-method MRI (84.13% and 90.48%, respectively) and molybdenum target X-ray (79.37% and 87.30%, respectively) ( < 0.05). The combined methodology specificity (96.83%) did not differ from single-method MRI (96.83%) or molybdenum target X-ray (95.24%) ( > 0.05). The T-wave peak (169.43 ± 32.05) and apparent diffusion coefficient (1.01 ± 0.23) were lower in the breast cancer group than in the benign tumor group (228.86 ± 46.51 and 1.41 ± 0.35, respectively). However, the peak enhancement rate (1.08 ± 0.24) and early enhancement rate (1.07 ± 0.26) were significantly higher in the breast cancer group than in the benign tumor group (0.83 ± 0.19 and 0.75 ± 0.19, respectively) ( 0.05).
Combined molybdenum target X-ray and MRI examinations for diagnosing breast cancer improved the diagnostic sensitivity and accuracy, minimizing the missed- and misdiagnoses risks and promoting timely treatment intervention.
早期乳腺癌患者常缺乏特异性临床表现，导致诊断困难。钼靶X线和磁共振成像（MRI）检查各有优势。因此，联合检查方法可能提高早期乳腺癌的诊断率。
探讨钼靶X线与MRI检查联合诊断乳腺癌的效能。
选取2019年3月至2021年4月在我院确诊为乳腺癌的患者，以及同期相同数量的乳腺良性肿瘤患者。两组患者均接受钼靶X线和MRI检查，并根据每项检查做出诊断。统计单项（X线或MRI）及联合（两种方法均用）诊断情况，并比较两组间MRI相关检查参数（T波峰、峰值及早期强化率、表观扩散系数）。
共纳入63例乳腺癌患者和63例乳腺良性肿瘤患者。MRI检测出53例乳腺癌病例和61例乳腺良性肿瘤病例。钼靶X线检测出50例乳腺癌病例和60例乳腺良性肿瘤病例。联合检查方法检测出61例乳腺癌病例和61例乳腺良性肿瘤病例。联合检查方法的敏感度（96.83%）和准确率（96.83%）高于单项检查的MRI（分别为84.13%和90.48%）及钼靶X线（分别为79.37%和87.30%）（P<0.05）。联合检查方法的特异度（96.83%）与单项检查的MRI（96.83%）及钼靶X线（95.24%）相比，差异无统计学意义（P>0.05）。乳腺癌组的T波峰（169.43±32.05）和表观扩散系数（仅为1.01±0.23）低于乳腺良性肿瘤组（分别为228.86±46.51和1.41±0.35）。然而，乳腺癌组的峰值强化率（1.08±0.24）和早期强化率（1.07±0.26）显著高于乳腺良性肿瘤组（分别为0.83±0.19和0.75±0.19）（P<0.05）。
钼靶X线与MRI联合检查诊断乳腺癌可提高诊断敏感度和准确率，最大限度降低漏诊和误诊风险，促进及时进行治疗干预。
